Figure 3
From: Hepatic ILC2 activity is regulated by liver inflammation-induced cytokines and effector CD4+ T cells
Regulation of hepatic ILC2 function by IL-1β/IL-12 or IL-25. (a) C57BL/6 mice received ConA and were analysed 8 hours later. Hepatic mRNA expression was analysed by quantitative RT-PCR and normalized to naive mice. (b) FACS-isolated hepatic ILC2 from IL-33-treated mice were cultured in the presence of IL-1β/IL-12 for 4 days. (c) Hepatic ILC2 were cultured in the presence of IL-2/IL-7 for 4 or 14 days. Thereafter, IL-1β and IL-12 were added and ILC2 were cultured for 4 further days. (d) Hepatic ILC2 were isolated from ConA-treated mice 24 h after induction of immune-mediated hepatitis and cultured in the presence of IL-1β/IL-12 for 4 days. GMFIs of IFNγ-, IL-5- or IL-13-expressing ILC2 were determined by flow cytometry and normalized to GMFIs of ILC2 cultured in the absence of IL-1β/IL-12. (e–h) Hepatic ILC2 were cultured in the presence of IL-25 and/or IL-33 for 4 days and analysed by flow cytometry. Histograms show frequency of cytokine-expressing hepatic ILC2. Bold line, antibody staining; filled graph, fluorescence minus one control. Mean ± SEM of 2–3 independent experiments are shown. (a–f) Mann-Whitney U test; (g,h) one-way ANOVA with post analysis by Tukey-Kramer test. *p < 0.05; **p < 0.01; ***p < 0.001; ns: not significant; nd: not detectable; GMFI: geometric mean fluorescence intensity, ConA: Concanavalin A; w/o: without.
